Mettler-Toledo International Inc. (MTD) | The Buildout — AI Infrastructure

——Mkt cap — · 52-wk —–— · YTD — · delayed
Updated Sep 22, 2026Q2 FY2026 reviewed
Mettler-Toledo makes precision laboratory and industrial instruments, including sensors used in semiconductor fabs and data-center cooling.
Organic +4%
Q2 organic growth, up from +1% in Q1; FY guide 3-4% organic.
Margin 29.3%
Q2 adjusted operating margin, up 100 bps excluding FX.
Service >$1B
Service revenue passed $1B annually; +7% organic in Q2.
AI edge is small
Semiconductor and data-center cooling: low single-digit % of revenue.
The Buildout Takeaway
Q2 reversed a soft first quarter — margins expanded, China accelerated, and management raised both the sales and EPS guides. The open question is what is left after price: organic guidance of 3-4% against price realization approaching 3% leaves volume of roughly 0-1%.
19 analysts·8 Buy11 Hold0 Sell
Median target$1,512  Range $1,194–$1,600 · 7 estimates

FY2026: local currency sales +4-5% (organic +3-4%) · adjusted EPS $47.15-$47.50 (+10-11%; +11-12% ex-FX) · share repurchases $875M
Important: The Buildout is a data analytics platform. Content is generated by algorithms and AI agents using public filings, earnings transcripts, and market data. This is not personalized investment advice.
Our View

The Verdict

Mettler-Toledo makes precision measuring instruments: laboratory balances, pipettes, titrators, pH meters and analytical instruments; process analytics sensors and analyzers; industrial weighing terminals and vehicle scales; and product inspection equipment such as metal detectors, X-ray systems and checkweighers. It also sells LabX software, which manages and analyzes the data those instruments generate, and a service business that maintains the installed base. Its most direct link to the AI buildout is Process Analytics — in-line sensors that monitor ultra-pure water in semiconductor fabs and cooling systems in data centers. Management sizes the semiconductor piece at a low single-digit share of revenue, so the AI link sits inside a much larger business serving pharmaceutical, food, chemical, retail and academic customers.

Market Cap—
Revenue (TTM)$4.1B
Revenue Growth+6.9%
EBITDA Margin (TTM)31.6%
Net Debt$2.1B
Earnings Beats7 of 7
P/E (TTM)—
EV/EBITDA (TTM)—

What We Like

  • Q2 FY2026 organic growth was 4%, up from 1% in Q1 and above the prior ~3% local-currency guidance; the FY2026 sales guide moved to 4-5% local currency.
  • Q2 adjusted operating margin was 29.3%, up 100 basis points excluding FX, with adjusted gross margin of 59.3%, up 90 basis points ex-FX and acquisitions.
  • Service revenue passed $1B annually for the first time, grew 7% organically in Q2, and is guided to high single digit for FY2026.
  • China grew 9% organically in Q2, led by double-digit Industrial, and the full-year guide was raised to high single digit.
  • Buybacks were raised to $875M, the high end of the prior $825M-$875M range, and adjusted free cash flow was $367M year-to-date.

What We’re Watching

  • Volume: full-year organic guidance of 3-4% against price realization approaching 3% implies roughly 0-1% unit growth.
  • The Americas: Q2 organic was +1%, and Q3 laps +9% organic in the region.
  • Short cycle: 1.5 months of backlog and immaterial unsatisfied performance obligations, so a demand air pocket reaches revenue within a quarter.
  • Second half: management said the H2 model holds "a little bit of conservatism or moderation slightly" to de-risk geopolitics, and an escalation is not in the forecast.
Bottom Line

The near-term business case strengthened in Q2: the Q1 margin contraction reversed, organic growth improved from 1% to 4%, and the company raised both the sales and EPS guides from an already raised base. Against that, the growth is price-led, the largest region is not growing organically, and the AI-infrastructure exposure that frames this page — Process Analytics into semiconductor fabs and data-center cooling — is a low single-digit share of revenue with no disclosed AI-specific growth rate. The open question is whether volume growth arrives before price normalizes toward management's stated long-term ceiling of no more than a 2% increase.

Next upQ3 FY2026 results are the next scheduled disclosure, guided to about 4% local-currency sales growth and adjusted EPS of $12.00 to $12.15. That quarter laps +10% organic Core Industrial and +9% organic Americas comparisons, so it tests whether Q2's inflection was demand-driven. Management has also pointed to an upcoming Analyst Day, where it has said it will discuss long-term pricing assumptions.
Last Quarter — Q2 FY2026

Earnings Beat

Q2 FY2026 revenue was $1,027.3M, with organic local-currency growth of 4% — up from 1% in Q1 — and adjusted EPS of $11.46, up 14%; reported EPS was $11.55 versus $9.76 a year ago. Gross margin was 61.4%, up from 56.6% in the prior quarter, and the company reported an adjusted gross margin of 59.3%, up 90 basis points excluding FX and acquisitions. Reported results include a one-time $52M gross IEEPA tariff refund benefit and a $28M refund to customers that reduced reported net sales by 3%, both excluded from adjusted figures.

MetricQ2 FY2026Q1 FY2026Q2 FY2025YoY
Revenue$1.0B$947M$983M+4.5%
Gross margin61.4%56.6%57.2%+420bps
EBITDA$347M$259M$296M+17.2%
EPS$11.53$8.35$9.77+18.0%
Organic local-currency growth+4%+1%n/a—
if you think about — it's part of our Process Analytics portfolio, and I think in total, is a low single-digit contribution in revenues. But it's doing extremely well. I mean all these buildouts in semiconductor, including, by the way, data centers where these things are also used for cooling systems. This is a great business opportunity for us, and we have a really strong go-to-market team there and really strong connection to customers.— Patrick Kaltenbach, CEO, 2026-07-31

Management tone: Management's framing changed between the two calls in the window. Q1 FY2026 was described as good performance in an increasingly uncertain market environment, with the Middle East war adding risk and customer delays in Americas core industrial. On the Q2 FY2026 call management said results were strong with better-than-expected organic growth, and that it is optimistic market conditions will gradually improve. It raised the China guide from mid-single to high single digit and, answering a question about the raise, volunteered that the second half contains "a little bit of conservatism or moderation slightly" tied to de-risking geopolitical concerns. It declined to quantify a Middle East buffer and gave no 2027 guidance.

Management Guidance

FY2026 guidance: local-currency sales growth of about 4-5%, reflecting organic growth of 3-4%. Adjusted EPS of $47.15 to $47.50, growth of 10-11%, or 11-12% excluding currency. Share repurchases were raised to $875M, the high end of the prior $825M-$875M range. Guidance excludes the tariff refunds. For Q3 FY2026, local-currency sales growth of about 4%, including about 0.5% from acquisitions, and adjusted EPS of $12.00 to $12.15.

Business Trajectory

Trajectory

Quarterly revenue has swung widely — $1,130M in Q4 FY2025, $947M in Q1 FY2026 and $1,027M in Q2 FY2026 — and reported figures label the revenue trajectory decelerating on a trailing basis. Underneath, the company's own organic growth went from 1% in Q1 to 4% in Q2, and the full-year organic guide of 3-4% sits above the realized first half. The composition is price-led: Q2 price realization was about 3% against 2.5% guided, acquisitions added about 1.5%, and China (+9% organic), Lab (+4% organic after a flat-organic Q1) and service (+7% organic) did the geographic and product-level work. Margins reversed a Q1 trough, with Q2 adjusted operating margin up 50 basis points as reported and 100 basis points ex-FX, helped by price, lower tariff rates versus the prior year and cost savings. Q3 guidance steps back to about 4% local currency because Core Industrial and the Americas lap +10% and +9% organic comparisons from Q3 2025.

Revenue & Margin Trajectory
RevenueGross margin$0$500$1.0B$651M$710M$595M$654M$699M$778M$661M$722M$735M$818M$680M$731M$754M$844M$649M$691M$807M$938M$804M$924M$952M$1.0B$898M$978M$986M$1.1B$929M$982M$942M$935M$926M$947M$954M$1.0B$884M$983M$1.0B$1.1B$947M$1.0B55%61%Q3'16Q4Q1'17Q2Q3Q4Q1'18Q2Q3Q4Q1'19Q2Q3Q4Q1'20Q2Q3Q4Q1'21Q2Q3Q4Q1'22Q2Q3Q4Q1'23Q2Q3Q4Q1'24Q2Q3Q4Q1'25Q2Q3Q4Q1'26Q2
RevenueGross margin$0$500$1.0B$651M$710M$595M$654M$699M$778M$661M$722M$735M$818M$680M$731M$754M$844M$649M$691M$807M$938M$804M$924M$952M$1.0B$898M$978M$986M$1.1B$929M$982M$942M$935M$926M$947M$954M$1.0B$884M$983M$1.0B$1.1B$947M$1.0B55%61%Q3'16Q4Q1'17Q2Q3Q4Q1'18Q2Q3Q4Q1'19Q2Q3Q4Q1'20Q2Q3Q4Q1'21Q2Q3Q4Q1'22Q2Q3Q4Q1'23Q2Q3Q4Q1'24Q2Q3Q4Q1'25Q2Q3Q4Q1'26Q2
Gross margin as reported.
Share Price — 12 Months
$500$1,000$1,500$052-wk high $1,492Sep '25DecMar '26JunSep '26
52-week range $1,026–$1,492.
Share Price — 12 Months
$500$1,000$1,500$052-wk high $1,492Sep '25DecMar '26JunSep '26
52-week range $1,026–$1,492.
The Numbers

The Model

The model projects FY+1 revenue of $4,232M and EBITDA of $1,333M, a 31.5% margin, then FY+2 revenue of $4,476M and EBITDA of $1,432M, a 32.0% margin. The near term is anchored on the raised FY2026 framework: 4-5% local-currency sales growth including 3-4% organic, price realization approaching 3%, and service and China both guided to high single digit. FY+2 carries a modest step-up, and the drivers management has flagged are the Lab recovery, Product Inspection's second-half pickup, and reshoring investment that management dates to 2027 and 2028.

Revenue & EBITDA Projections
REVENUE$4.0B$4.2B$4.5BFY25FY+1 (E)FY+2 (E)EBITDA & MARGIN$1.2B$1.3B$1.4B32.0%FY25FY+1 (E)FY+2 (E)
REVENUE$4.0B$4.2B$4.5BFY25FY+1 (E)FY+2 (E)EBITDA & MARGIN$1.2B$1.3B$1.4B32.0%FY25FY+1 (E)FY+2 (E)
Solid bars are reported actuals; outlined bars are model projections — not company guidance.
MetricFY2025Next FY (E)Following FY (E)
Revenue$4.0B$4.2B$4.5B
YoY Growth—+5.1%+5.8%
EBITDA$1.2B$1.3B$1.4B
EBITDA Margin30.9%31.5%32.0%

Projections are the median of 5 independent model runs. The model’s revenue sits 1.5% above analyst consensus.

FY2026 guidance: local-currency sales growth of about 4-5%, reflecting organic growth of 3-4%. Adjusted EPS of $47.15 to $47.50, growth of 10-11%, or 11-12% excluding currency. Share repurchases were raised to $875M, the high end of the prior $825M-$875M range. Guidance excludes the tariff refunds. For Q3 FY2026, local-currency sales growth of about 4%, including about 0.5% from acquisitions, and adjusted EPS of $12.00 to $12.15.

What Could Go Right — and Wrong

What good looks like
  • Reshoring converts from RFQs into orders, with investment spending management dates to 2027 and 2028.
  • Lab inflects from flat organic in Q1 to +4% organic in Q2; it is the largest product category.
  • Service keeps compounding at high single digits, adding recurring revenue and installed-base stickiness.
  • China stays at high-single-digit growth, led by double-digit Industrial.
  • The IEEPA tariff refund landed at size — $52M gross in Q2, with $28M of it refunded to customers.
What could go wrong
  • Volume growth stays near zero: full-year organic guidance of 3-4% against price realization approaching 3%.
  • The Americas remains soft, with Q2 organic up only 1% and the region lapping a +9% organic comparison in Q3.
  • Customer delays recur; with 1.5 months of backlog, a delayed decision lands in the same quarter.
  • Price normalizes toward management's stated long-term ceiling of no more than 2% without volume taking over.
  • Service grows faster than products at a 53.3% gross margin versus 60.7% on products, working against the blended rate.
What’s Next

Looking Ahead

Over the next twelve months the company's own timeline centers on Q3 FY2026 results, guided to about 4% local-currency sales growth and adjusted EPS of $12.00 to $12.15, and on Product Inspection and China Lab improving in the second half as management expects. An Analyst Day is upcoming, where management has said it will discuss long-term pricing assumptions and where it has already capped expectations at no higher than a 2% price increase. No 2027 guidance has been given, and the reshoring spending management points to is dated to 2027 and 2028 rather than the next twelve months.

Catalysts
  • Q3 2026Q3 FY2026 results — Guided to ~4% local-currency sales and $12.00-$12.15 adjusted EPS.
  • 2H 2026Product Inspection pickup — Q2 organic was +1%; management expects the line to pick up again in the second half.
  • 2H 2026China Lab improvement — Management expects biopharma and academia demand to improve by year-end.
  • UndatedAnalyst Day — Where long-term pricing assumptions were deferred; 2% ceiling stated.
  • UndatedIEEPA refund resolution — ~$53M of claims submitted; a significant portion may pass to customers.
  • 2027-2028Reshoring investment cycle — Facility groundbreaking and investment spending dated to 2027 and 2028.
Numbers

Financials

Annual Summary

MetricFY2024FY2025TTMYoY
Revenue$3.9B$4.0B$4.1B+4.0%
Gross Margin58.1%57.5%58.3%62bps
EBITDA$1.3B$1.2B$1.3B-0.5%
EBITDA Margin32.3%30.9%31.6%139bps
Net Income$863M$869M$906M+0.7%
Free Cash Flow$864M$849M$864M—
Net Cash————

Key Ratios (Trailing)

Valuation
  • P/E TTM—
  • EV/EBITDA TTM—
  • EV/Revenue TTM—
  • Price/FCF TTM—
Profitability
  • Gross Margin (TTM)58.3%
  • EBITDA Margin (TTM)31.6%
  • Net Margin (TTM)21.9%
  • ROIC44.7%
  • FCF Conversion66.2%
  • SBC / Revenue0.6%
Reference

The Company

Mettler-Toledo is a supplier of precision instruments and services, describing itself in its FY2025 10-K as a leading global supplier with strong leadership positions in all of its businesses and what it believes are global number-one market positions in most of them. Its products span laboratory balances with weighing ranges from one ten-millionth of a gram up to 64 kilograms, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzers, density and refractometry analyzers, thermal analysis systems, UV/VIS spectrophotometers and cell counters. On the industrial side it sells weighing instruments and terminals, transportation and logistics dimensioning equipment, vehicle scale systems capable of measuring up to 500 tons, and product inspection equipment — metal detectors, X-ray systems, checkweighers and camera-based imaging. It also sells LabX software and retail weighing solutions, and it services the installed base. Management says about 50% of sales go into production and about 20% into QA/QC, with chemicals under 15% of sales and Product Inspection about 70% food manufacturing.

The company operates through five geographic reportable segments — U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations and Other Operations — and its 10-K describes its listed properties as serving primarily as manufacturing facilities or shared service centers, with space for service, sales and marketing, and administration. Products are sold in more than 140 countries with a direct presence in approximately 40. It cites a productivity program called SternDrive among the cost savings behind its margin execution.

Business Segments

Laboratory
FY2026 guided to low-to-mid single digit
Balances, pipettes, titrators, pH meters, analytical instruments and LabX software for QA/QC and research labs. Q2 organic growth was 4% after a flat-organic Q1.
Growth driver: Pharmacopeia-driven replacement plus biopharma recovery
Industrial
FY2026 guided to low-to-mid single digit
Weighing instruments and terminals plus Product Inspection — metal detectors, X-ray systems, checkweighers and camera-based imaging. Q2 Core Industrial grew 4% organically, Product Inspection 1%.
Growth driver: Automation, digitalization and reshoring RFQ activity
Service
FY2026 guided to high single digit
Installed-base service, repair and support across the instrument portfolio, exceeding $1B in annual revenue and growing 7% organically in Q2.
Growth driver: Installed-base data and AI-supported engineer knowledge base

Competitive Landscape

The 10-K states that MTD has strong leadership positions in all of its businesses and that it believes it holds global number-one market positions in most of them. The one competitive claim made on the tape concerns service: management says customers can get certain things only at MT because of its access to installed-base data, which it says none of its competitors have when it comes to servicing instruments. No competitor is named in the company's filings in this material, and the code-computed criticality assessment judges that MTD's products could be replaced by alternatives within a few quarters.

  • Named in the code-computed criticality assessment as an alternative source for MTD's products; not discussed in company filings.
  • Also named in the criticality assessment as a replacement alternative; not discussed in company filings.
The FY2025 10-K names no competitor; Veralto and ABB appear only in the code-computed criticality assessment, which judges the products replaceable within a few quarters.

Supply Chain

MTD buys components for its instruments and its 10-K says some items come from limited or single sources, though no counterparty is named anywhere in the delivered material. On tariffs it sits between its suppliers and its customers, absorbing cost, passing some through and pursuing refunds from both ends. No supplier and no customer is named.

Analysis updated Sep 22, 2026, reviewing Q2 FY2026. Prices delayed. Built with The Buildout’s published methodology. Not investment advice. No positions held. © The Buildout 2026.

More on MTD: Earnings recap